Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static-preview.hindawi.com/articles/jir/volume-2020/5269787/figures/5269787.fig.004a.svgz" name="5269787.fig.004a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Monotherapy (sex subgroup)</td></tr><tr class="fig-image" id="b"><td><object data="https://static-preview.hindawi.com/articles/jir/volume-2020/5269787/figures/5269787.fig.004b.svgz" name="5269787.fig.004b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Combination therapy (sex subgroup)</td></tr></table>

<div>Forest plot of the hazard ratio comparing overall survival in patients who received PD-1/PD-L1 inhibitors versus control by sex: (a) monotherapy group and (b) combination therapy group.</div>

Journal of Immunology Research

fig4

Figure 4

Figure 4: Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis 

Figure 4 | Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis 